DelveInsight’s, “Advanced Ovarian Cancer Pipeline Insight 2023” report provides comprehensive insights about 60+ companies and 70+ pipeline drugs in the Advanced Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Advanced Ovarian Cancer Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Advanced Ovarian Cancer Pipeline landscape @ Advanced Ovarian Cancer Pipeline Outlook Report
Advanced Ovarian Cancer Overview
Advanced Ovarian Cancer means that cancer has spread outside the ovary. It may have spread within the pelvis or abdomen, or further away to other parts of the body such as the lungs. Some women have Advanced Ovarian Cancer when they are first diagnosed, and treatment can cure their cancer. This depends on several factors, including the exact stage of cancer.
Recent Developmental Activities in the Advanced Ovarian Cancer Treatment Landscape
For further information, refer to the detailed Advanced Ovarian Cancer Drugs Launch, Advanced Ovarian Cancer Developmental Activities, and Advanced Ovarian Cancer News, click here for Advanced Ovarian Cancer Ongoing Clinical Trial Analysis
Advanced Ovarian Cancer Emerging Drugs Analysis
Oregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial. In a randomized Phase 2 clinical trial of 97 patients, treatment with Oregovomab in combination with chemotherapy had demonstrated a highly statistically significant and clinically meaningful outcome for both progression-free and overall survival compared to standard of care chemotherapy (carboplatin and paclitaxel). The risk of progression and of death was reduced by more than 50% when compared to control arm, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapy regimen. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of advanced ovarian cancer.
SC10914 is a highly selective inhibitor of PARP enzymes, including PARP1 and PARP2. SC10914 has a similar structure with olaparib. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Advanced Ovarian Cancer.
Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Advanced Ovarian Cancer.
Advanced Ovarian Cancer Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for advanced ovarian cancer. The companies which have their advanced ovarian cancer drug candidates in the most advanced stage, i.e. phase III include, OncoQuest.
Find out more about the Advanced Ovarian Cancer Pipeline Segmentation, Therapeutics Assessment, and Advanced Ovarian Cancer Emerging Drugs @ Advanced Ovarian Cancer Treatment Landscape
Scope of the Advanced Ovarian Cancer Pipeline Report
Dive deep into rich insights for drugs for Advanced Ovarian Cancer Pipeline Companies and Therapies, click here @ Advanced Ovarian Cancer Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on advanced ovarian cancer Mergers and acquisitions, advanced ovarian cancer Licensing Activities @ Advanced Ovarian Cancer Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/